Another previous case report demonstrated that an advanced NSCLC patient whose EML4-ALK fusion was detected after acquired resistance to osimertinib therapy had a durable response to treatment with the ALK inhibitor ensartinib [43]. Here, ALK is linked to non-small cell lung carcinoma.